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Primary Central Nervous System 




Neuroblastoma is one of the most common solid tumour in the paediatric age 
group. Central nervous system (CNS) involvement in neuroblastoma is commonly 
due to metastasis from the extracranial primary. Primary CNS Neuroblastoma 
(PCNS-NB) is a rare entity and highlights errors in development of neural crest 
cells and CNS. A lot has been published since the first description of PCNS-NB four 
decades ago. Over the years, neuroscientists, geneticists, and clinicians have improved 
the understanding of PCNS-NB. PCNS-NB is an enigmatic entity with variable 
presentation, epidemiology, clinical features and outcomes. Recent update in knowl-
edge is seen in 2016 WHO classification of CNS tumours with reclassification of CNS 
neuroblastoma. It further subclassified different histological variants of PCNS-NB 
and its molecular correlates. Most common histological subtype of PCNS-NB is neu-
roblastoma followed by ganglioneuroblastoma. Studies support the view that younger 
age group, less number of lesions, ganglioneuroblastoma histology subtype and surgi-
cal management are good prognostic indicators. This chapter provides an updated 
overview of epidemiology, clinical features, histological and molecular diagnosis, and 
outcomes of PCNS-NB in addition to the role of adjuvant therapy.
Keywords: Primary central nervous system neuroblastoma, Ganglioneuroblastoma, 
CNS PNET, CNS Neuroblastoma with FOX-R2, CNS embryonal tumours
1. Introduction
1.1 Background
Neuroblastoma is one of the most common solid extracranial tumour in the 
paediatric age group. Key characteristics of neuroblastoma include onset at an early 
age, aggressive behaviour, tendency to metastasize, regress spontaneously in infancy, 
and variable presentation [1, 2]. Neuroblastoma is associated with grim prognosis 
with 60% of patients at presentation having only 5–15% chance of long term 
survival [3]. Most of the cases of central nervous system neuroblastoma are due to 
metastasis from the extracranial site. Primary central nervous system neuroblastoma 
(PCNS-NB) is uncommon as metastatic intracranial neuroblastoma (MIC-NB). It is 
essentialto understand that the manifestation of neuroblastoma varies with the site 
of origin [4, 5]. Therefore, a PCNS-NB has different epidemiology, clinical features, 
and outcomes compared to the MIC-NB. There is emerging evidence on various 
molecular and genetic profiling of neuroblastoma which dominates the clinical 
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picture. At the end of this chapter, the readers will acquire updated information on 
the PCNS-NB, various modes of presentation, and treatment outcomes in light of 
current evidence. Recent research areas, molecular and genetic findings, and areas 
with gaps of knowledge are also highlights of this chapter.
1.2 History
Horten, and Rubinstein provided the earliest large scale description of 35 cases of 
PCNS-NB in 1976 [6]. Their description includes the gross description of the tumour, 
clinical features and management, but lacks the description of the evolution of these 
tumours. They described three variants of PCNS-NB based on connective tissue 
stroma and cells with ganglionic differentiation. The classic variant is similar to the 
peripheral neuroblastoma with relatively high proportions of cells with ganglionic 
differentiation and high frequency of Homer Wright rosettes. A desmoplastic variant 
consists of tumours composed of intense connective tissue stroma. A transitional 
variant consists of tumours with both classical and desmoplastic features [6]. They 
found 40% to have metastasis along the craniospinal axis at autopsy and reported 
PCNS-NB to be similar to cerebellar medulloblastoma [6]. Overall three years 
survival is reported to be 60% and five years survival at 30% [7]. Most of these stud-
ies have probably clubbed other tumour types (Medulloblastoma, undifferentiated 
ependymoma, and sarcoma) in the expectedstandard category of CNS neuroblas-
toma; hence, they do not provide a precise analysis of this rare entity. Further, most 
studies on PCNS-NB have variable reporting on the treatment modalities, surgical 
options, extent of resection, adjuvant chemoradiation and long term outcomes. 
Therefore PCNS-NB is still one of the least understood neoplasms of the CNS.
1.3 Definition
In 2016 WHO classification of CNS tumours, CNS neuroblastoma is classified 
under neuronal and paraneuronal tumours with ICD 0 code of 9500/3 [8]. The 
first four digits of the ICD 0 code indicates the specific histologic term and the 
fifth digit after/indicates the nature of the tumour with 3 indicating malignant 
behaviour. Primary central nervous system neuroblastoma (PCNS-NB) is defined 
as an embryonal tumour with poorly differentiated neuroepithelial cells, groups of 
neurolytic cells and variable neuropil rich stroma [8]. These tumours carrier grave 
prognosis and usually portrays aggressive behaviour [4]. Ganglioneuroblastoma 
is a subtype of neuroblastoma and defined by the International Neuroblastoma 
Pathology Classification framework based on the Shimada system [9, 10].
1.4 Epidemiology
Neuroblastoma is primarily a neoplastic disease of the peripheral nervous 
system. Oncologists often describe neuroblastoma as enigmatic heterogenous 
neoplasia due to its unique features and biological properties of spontaneous 
regression, aggressive progression and maturation [2, 11, 12]. These variable factors 
serves as the prognostic factors in the cure and outcome of neuroblastoma [12, 13]. 
Epidemiology of PCNS-NB differs from the heterogeneous group of neuroblastoma 
[2]. In general, neuroblastoma is diagnosed most commonly in the first year of life 
with a median age of diagnosis at 18 months, with 90% of children with neuroblas-
toma presenting under ten years of age at an estimated prevalence of 25–50 cases 
per million individuals [14, 15]. However, only cases reports and case series of few 
patients exist for PCNS-NB. To understand the epidemiology and natural history 
of PCNS-NB, Lu et al. [16] conducted a population-based study using the SEER 
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(Surveillance, Epidemiology and End Results) program. The annual incidence 
of PCNS-NB has shown a downward trend from 1973 to 2013, probably because 
many of these tumours were earlier labelled as medulloblastoma, undifferenti-
ated ependymoma or sarcoma due to inferior diagnostic methods [16]. As per the 
SEER program, the annual age-adjusted incidence rate was 0.12 per 1,000,000 
persons in 2013 and the incidence decreased with age with peak incidence occur-
ring in infants [16, 17]. No gender or racial variation has been reported for the 
occurrence of PCNS-NB. In the study by Lu et al. [16], 40.7% of patients belonged 
to the age group 1–9 years and only 8.2% were of age ≥ 40 years. Mean age of 
patients in reported literature of PCNS-NB is around five years with slight female 
preponderance.
1.5 Tumour characteristics
Histologically most common histology of the PCNS-NB is neuroblastoma, 
followed by ganglioneuroblastoma. In a large population-based study brain (53.6%) 
was found to be the most common site of PCNS-NB, followed by other nervous sys-
tem tumours (46.4%). Tumours at sites in the nervous system other than the brain 
tend to occur in a much younger age group, extensive and more aggressive [16].
1.6 Etiopathogenesis
Neuroblastoma arises from the primitive elements of the neural crest and 
therefore predominantly affects the neural crest derivatives, i.e. adrenals and sym-
pathetic ganglia. The central nervous system (CNS) can be involved in the form of 
primary CNS neuroblastoma, CNS metastasis secondary to occult primary, primary 
intraorbital neuroblastoma from the ciliary ganglion, metastatic neuroblastoma to 
the orbit, primary intraspinal neuroblastoma originating from dorsal root ganglion, 
metastatic spinal neuroblastoma and remote paraneoplastic effects such as myo-
clonic encephalopathy. WHO classification of CNS tumours (2007) enlist CNS-
PNET-NOS (not otherwise specified) and four variants of CNS PNET which can 
be differentiated based on molecular characteristics as CNS neuroblastoma, CNS 
ganglioneuroblastoma, medulloepithelioma and ependymoblastoma [8]. According 
to the 2016 WHO classification of CNS tumours, CNS neuroblastoma is classified as 
an embryonal tumour [8]. CNS-PNET was not found to be a separate entity after the 
DNA methylation profile of most of the PNET tumours. However, when most well-
defined CNS tumours with similar DNA methylation profiles were excluded, there 
were few unknown tumours, one of which is CNS neuroblastoma [18]. This new 
molecular entity after DNA methylation was designated as “CNS neuroblastoma 
with FOX-R2 activation” (CNS NB-FOXR2) [18]. Various studies have elucidated the 
mechanism for development of CNS disease in a patient of neuroblastoma. Odeone-
Filho hypothesised that meningeal surface can act as potential direct pathyway for 
entry of neuroblastoma cells in the CNS, based on a case with CNS neuroblastma in 
completely controlled systemic disease.
The development of PCNS-NB does not follow two-hit models usually suggested 
in neuro-oncology. Instead, it results from the persistence of embryonic cell, which 
should have differentiated or undergone apoptosis during the ordinary course of 
CNS development. Bcl-2 family of genes regulate apoptosis, and its continued 
expression appears to play a significant role in the pathogenesis of neuroblastoma 
and its resistance to chemotherapeutic drugs. Other genetic factors implicated 
in neuroblastoma development include cytogenetic aberrations in neuro crest 
development, partial monosomy for the short arm of chromosome 1, and long 
arms chromosomes 11 and 14. Shimada system of classification of neuroblastoma 
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Stage 1 Complete gross excision of localised tumour, 
with or without positive microscopic margins
Negative ipsilateral non-adherent lymph 
node(s) (lymph node(s) attached to and 
removed with the primary tumour may be 
positive)
Stage 2A Incomplete gross excision of localised 
tumour
Negative ipsilateral non-adherent lymph 
node(s) (lymph node(s) attached to and 
removed with the primary tumour may be 
positive)
Stage 2B Complete or incomplete gross excision of 
localised tumour
Positive ipsilateral non-adherent lymph 
node(s); contralateral lymph node(s) 
negative for tumour
Stage 3 a. Unresectable unilateral tumour infiltrating 
across the midline
OR
b. Localised unilateral tumour
OR
c. Unresectable midline tumour with 
bilateral extension
a. Positive or negative regional lymph 
node(s)
OR
b. Contralateral positive regional lymph 
node(s)
OR
c. May be “unresectable” due to positive 
bilateral lymph node(s)
Stage 4 Any primary tumour with involvement of 
distant lymph nodes, bone, bone marrow, 
liver, skin, and/or other organs (except 4S)
Stage 4S Any localised primary tumour with 
involvement of skin, liver, and/or less than 
10% of bone marrow cellularity




International neuroblastoma staging system.
and International Neuroblastoma Staging System is illustrated in Tables 1 and 2, 
respectively. There are even reports of neuroblastoma occurring post-radiation in 
children and adults [19–22].
1.7 Clinical features
Patients usually present with features of intracranial mass lesion and raised intra-
cranial pressure. Secondary neuroblastoma is mainly extra-axial pathology. It presents 
as a bony lesion involving the calvaria and extradural mass lesion. However, the lesion 
can produce haemorrhagic deposits in the parenchyma and increase intracranial 
Type Description
I Neuroblastoma (Schwannoma stroma-poor)
II Ganglioneuroblastoma, intermixed (Schwannoma stroma-rich)
III Ganglioneuroma (Schwannoma stroma-dominant)




The international neuroblastoma pathology classification of neuroblastoma (Shimada system) [1].
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pressure and altered neurological status. Presentation with seizures is not very com-
mon. Extra-axial deposits of neuroblastoma present with neurological deficits due to 
compression of eloquent brain parenchyma. These lesions can also have sutural dias-
tasis due to epidural deposits along the sutures and do not indicate raised intracranial 
pressure. The status of venous sinuses should be evaluated with CT and MR imaging 
in patients with sutural diastasis as increased intracranial pressure will show compres-
sion of venous sinuses, which will be absent in sutural diastasis due to neuroblastoma 
deposits [23]. PCNS-NB being intra-axial pathology presents headaches, vomiting, 
ill localised features, localising features based on cerebral location, and raised intra-
cranial pressure and seizures. Many of these patients present with clinical features on 
intraventricular mass lesions and hydrocephalus. There can be sudden worsening in 
the neurological status in the event of a haemorrhage within the lesion.
2. Imaging and histopathology
2.1 Imaging
A typical CT picture of PCNS-NB shows a large intra-axial lesion with calcifica-
tions, cystic degeneration and areas of haemorrhage [24]. Perilesional oedema may 
be limited as compared to the size of the lesion [24]. On post-contrast CT images, uni-
form enhancement is seen in solid masses, and heterogeneous contrast enhancement 
is seen in lesions with cystic degeneration and extensive calcifications. Additionally, 
intraventricular lesions can demonstrate subependymal masses and help in dif-
ferentiating these lesion from other differential diagnoses of intraventricular mass 
lesions. MR imaging of these tumours shows inhomogenous intensities on both T1 
and T2-weighted images [24]. Areas of calcification and flow voids can be challenging 
to identify in classical MRI and can be seen well in susceptibility-weighted images 
(SWI). Different duration of haemorrhage within the lesion can be appreciated well 
on MR images. On gadolinium-enhanced T1-weighted MR imaging, tumour mass 
shows inhomogeneous contrast enhancement. Contrast MRI further helps in identi-
fying subependymal enhancement, recurrence around previously operated sites and 
leptomeningeal spread. Imaging also helps to assess ventricular size as these tumours 
grow towards the ventricles and many patients develop secondary hydrocephalus. 
As there are no pathognomonic image findings of PCNS-NB, it should be kept in the 
differential diagnosis of any patients with the clinical possibility of PCNS-NB and 
intra-axial, intraventricular or periventricular mass lesion [24]. Primary CNS neuro-
blastoma is usually intra-axial and spread through CSF pathways, whereas second-
ary neuroblastoma is mainly extra-axial but can have haemorrhagic deposits in the 
parenchyma and sutural diastasis on CT due to epidural deposits [23].
2.2 Histopathology
Grossly PCNS-NB tumours are massive, discrete, firm, and cystic in 
appearance. Histopathology of a newly designated group of tumours as CNS 
neuroblastoma which were earlier designated as CNS neuroblastoma or CNS 
ganglioneuroblastoma in 2007 WHO classification scheme [8] showed distinct 
characteristics. CNS NB-FOXR2 showed an embryonal architecture with small cells 
and areas of differentiation in neuropil, neurocytic cells and ganglion cells with 
uniform expression of OLIG2 and neuronal antigen synaptophysin (Figure 1) [13, 
18]. Histologically ganglioneuroblastoma consists of ganglion cells with different 
degrees of differentiation, Nerve sheath, glial fibres, and malignant neuroblastoma 
cells [9, 25–27]. Common pathological picture of ganglioneuroblastoma includes 
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ganglion cells with a double nucleus, highly infiltrated and proliferated cells with 
dense chromatin [28, 29]. Further ganglioneuroblastomata have two histological 
subtypes: undifferentiated type has a small round to oval cells with hyperchromatic 
nuclei, and poorly differentiated type has a large round to oval spindle-shaped cells 
with pale staining nuclei [30, 31].
2.3 Discussion
Neuroblastoma is an enigmatic and one of the most common malignant solid 
tumour of the paediatric age group. Neuroblastoma is a disease with a grim prog-
nosis, and the outcome has not changed significantly in the past two decades. 
Neuroblastoma teaches us essential aspects of CNS and neural crest development. 
Primary CNS Neuroblastoma (PCNS-NB) is a rare subtype of neuroblastoma with 
variable classification. It includes CNS neuroblastoma and ganglioneuroblastoma. 
In 2016 WHO classification of CNS tumours, PCNS-NB is classified as embryonal 
tumours. Embryonal tumours with the exception of medulloblastoma has been 
reclassified based on molecular alterations, for example atypical teratoid rhabdoid 
tumour (AT/RT) characterised by SMARCB1 or SMARCA4 inactivation, C19MC 
altered and/or LIN28A expressing embryonal tumour with multi-layered rosettes 
(ETANTR) and CNS neuroblastoma/Ganglioneuroblastoma without specific 
histological features or molecular alterations [8]. Based on global transcriptional and 
methylation profiling four tumour entities have been proposed: CNS neuroblastoma 
with FOXR2 activation (NB-FOX-R2), High grade neuroepithelial tumour with MN1 
alteration (HGNET-MN1), high grade neuroepithelial tumour with BCOR alteration 
(HGNET-BCOR), and Ewing sarcoma family tumour with CIC alteration (EFT-CIC) 
[18]. CNS neuroblastoma rarely contains GFAP positive cells which are usually reac-
tive astrocytes and most of the NB-FOX-R2 tumours are neuroblastic differentiation 
and contains neurocytic cells with poorly differentiated neuropil rich stroma and 
embryonal architecture [32]. However, there are reports of CNS neuroblastoma with 
GFAP positive tumour cells demonstrating both neuronal and glial nature, though 
the clinical significance of such entity is unknown [32]. Since, PCNS-NB is a rare 
entity and usually present in younger age group, little is known about its treatment 
protocols, prognostic factors and patient risk stratification. Review of literature 
suggests that PCNS-NB preferentially occurs in the supratentorial space with 
involvement of frontal and parietal region [4]. Clinical presentation of PCNS-NB is 
usually as per the most common site of involvement. Since, most of the PCNS-NB 
prefers supratentorial location preferably in the frontal and parietal region, patients 
Figure 1. 
Various routes for entry of neuroblastoma cells, and its spread to and within CNS.
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usually manifest with focal neurological deficits, bony lesions, irritative symptoms 
in form of seizures and symptoms of raised intracranial pressure due to mass effect. 
These effects of raised intracranial pressure and mass effect are less pronounced in 
infancy in younger children because of compensatory and adaptive mechanism of 
surrounding brain structures. Metastatic presentation of PCNS-NB is reported only 
in couple of cases via cervical lymph nodes and cerebrospinal fluid [33]. Therefore 
in evaluation of PCNS-NB complete screening neuroimaging of whole cranio-spinal 
neuroaxis should be performed to rule out any metastatic spread through the CSF. In 
general, PCNS-NB appears like other solid CNS tumours in brain MRI. They can be 
purely solid or solid-cystic. Solid component of tumours are T1 and T2 hypointense 
with mild hyperintensity on DWI sequences and inhomogenous contrast enhance-
ment and increased relative cerebral blood volume (rCBV) on perfusion images. 
Cystic component of tumour appears hyperintense due to hyperproteieic content. 
MRS sequences show increase in choline peak and inversion of choline/NAA ratio, 
but none of these imaging parameters are unique to the PCNS-NB. It is essential to 
understand that there are no tumour markers or radiological markers which can reli-
ably differentiate PCNS-NB from other tumours. Two essential criteria for defining 
PCNS-NB is presence of classical histology and absence of systemic neuroblastoma.
The outcome of PCNS-NB depends on age, the tumour’s aggressiveness, tumour 
subtype, locations, histology and extension. Surgery is the treatment of choice, 
and adjuvant radiotherapy improves survival. Safety and outcome of radiotherapy 
are not well established in infants and younger population but need to be viewed in 
light of improved survival obtained by adjuvant radiotherapy.
3. Summary and perspectives
3.1 Prognostic factors
Younger age group, a limited number of lesions, ganglioneuroblastoma subtype 
and surgical management, are found to be positive prognostic factors in PCNS-NB. 
Neuroblastoma has complex heterogeneous nature with varied prognosis, infants 
<1 year of age tend to have maximum overall survival with the tumour spontane-
ously regressing in some infants on the one hand and having widespread metastasis 
on the other hand [2, 12]. Studies have found best overall survival in infants <1 year 
of age and relatively less short term adverse events in age > 40 years with a 1-year 
survival of 57.2% [16].
3.2 Management options
In the population-based studies, patients with extensive disease, multiple 
lesions, and metastasis were more often offered conservative management as 
surgical excision was not feasible [16]. Surgical excision is often referred to as the 
first line of management in the treatment of PCNS-NB, whenever feasible [4]. 
Differentiation in ganglioneuroblastoma lies in between malignant neuroblas-
toma and benign ganglioneuroma. Ganglioneuroblastoma subtype is found to be 
associated with a good prognosis. Studies show that the ganglioneuroblastoma 
subtype rarely infiltrates and tends to be localised with less incidence of metastatic 
deposits [16, 34]. This explains that patients with this subtype are likely to be 
offered surgery and benefit from surgical excision with overall better survival. 
Ganglioneuroblastoma typically has a high invasive behaviour but slower multipli-
cation rate and the asymptomatic period of up to 60 months has been reported after 
surgical excision [35, 36].
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3.3 Adjuvant radiotherapy
Adjuvant radiotherapy of the primary site is the standard of care in high-risk 
neuroblastoma patients to reduce the risk of recurrence [6, 37]. Bennett et al. [7] 
suggested prophylactic irradiation craniospinal axis due to high propensity of CSF 
metastasis and recurrence of PCNS-NB [6]. However, the role of radiotherapy in 
PCNS-NB is not well elucidated. This is because the side effects of radiotherapy in 
the younger age group of radionecrosis and cognitive decline limit its applicabil-
ity. Lu et al. [16] found a variable practice pattern of adjuvant radiotherapy and 
reported better survival and no significant side effects of radiotherapy, contrary to 
other studies.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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